The use of CRISPR/Cas9* genome editing for the creation of unique rodent models of human disease has revolutionized the field - but every revolution raises challenging issues.
Join our presentation as we review the latest considerations for the technology as it applies to in vivo research and answer key questions including:
- CRISPR/Cas9 IP/license constraints: how does it impact your project?
- Is it compatible with the goals of the 3Rs?
- Does CRISPR allow for the generation of relevant models?
- Jean Cozzi, PhD, Innovation Manager, Charles River
*CRISPR/CAS9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.